BiOMViS Srl is a Biotech Company committed to foster prophylactic and immunotherapeutic interventions in infectious diseases and cancer.
BiOMViS has proprietary technologies on the use bacterial Outer Membrane Vesicles (OMVs) as vaccine platform. OMVs are closed spheroid particles released by Gram-negative bacteria in the extracellular milieu. OMVs are …
BiOMViS Srl offers external partners highly qualified services in several research areas, including molecular and cell biology, microbial fermentation and cell culture, protein purification, immunological assays (ELISA, T cell analyses), …
BiOMViS OMV platform is based on non-pathogenic E. coli strains which have been genetically modified to release large quantities of OMVs carrying a characterized pool of endogenous proteins. An armamentarium …
Tumors develop as a consequence of gene mutations that alter cellular morphology and metabolism. These mutations, that give tumors a selective growth advantage over healthy tissues, potentially represent tumors’ “Achilles’ …
1. Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. Grandi A, Tomasi M, Zanella I, Ganfini L, Caproni E, Fantappiè L, Irene C, Frattini L, Isaac …
 |
| BiOMViS Srl is located at the Toscana Life Sciences (TLS) Scientific Park (Siena, Italy), where it has access to fully equipped laboratories and office space and to a variety of high-tech services, including Flow cytometry, Electron Microscopy, Confocal Microscopy, Proteomic and Mass Spectrometry, Protein Purification. |
